About Cardiosense
Cardiosense is a digital health company that develops AI-powered cardiac monitoring technology to detect early signs of heart disease and facilitate personalized therapy. Their platform leverages wearable sensing technology, advanced signal processing, and deep learning to convert raw physiological data into clinical intelligence. The company’s primary medical-grade wearable monitor, CardioTag, is designed to noninvasively capture three distinct physiological signals: electrocardiogram (ECG), photoplethysmogram (PPG), and seismocardiogram (SCG). This multimodal sensor integration, combined with AI-driven digital biomarkers, provides comprehensive cardiac assessment capabilities.
Cardiosense’s initial focus is on improving heart failure management. Their CardioTag device and PCWP Analysis Software™ recently received FDA De Novo classification, enabling non-invasive estimation of Pulmonary Capillary Wedge Pressure (PCWP) at the point of care. This technology aims to provide clinicians with real-time, objective hemodynamic insights, allowing for more precise and proactive management of heart failure patients, potentially reducing hospitalizations and optimizing medical therapy. The company’s approach is to provide timely clinical decision support across various care settings, including emergency department assessment, inpatient management, discharge planning, and outpatient/at-home monitoring.
Focus Areas
Business Intelligence
| Key Investors | Broadview Ventures, Hatteras Venture Partners, Laerdal Million Lives Fund, OSF Ventures, UnityPoint Health Ventures, Portal Innovations, Alkeon Capital, BoxOne Ventures, Buckley Ventures, Matt Ocko, Daniel Gottlieb, Endeavor Venture Funds, BayMed Venture Partners, GTF Ventures, Oakwood Circle Ventures, Matter |
| Technology | AI platform leveraging wearable sensing technology, advanced signal processing, and deep learning to convert raw physiological data into clinical intelligence. Cloud-native approach for data aggregation and analysis. |
| FDA Clearances | 2 cleared products (estimated) |
What Physicians Need to Know
For physicians, Cardiosense offers a revolutionary approach to heart failure management by providing noninvasive, real-time insights into Pulmonary Capillary Wedge Pressure (PCWP). This allows for earlier detection of worsening conditions, more precise and proactive management of heart failure, and optimization of medication protocols. The CardioTagu2122 device is easy to use and provides rapid, accurate PCWP readings, validated against right heart catheterization. This can lead to timely clinical decision support, reduced heart failure hospitalizations, and improved long-term patient outcomes. The ability to monitor PCWP remotely also facilitates better outpatient and at-home care, detecting and treating worsening conditions before symptoms arise.
CardioSense AI, a related entity or product, mentions seamless integration with existing Electronic Medical Record (EMR) systems for AI-powered ECG interpretation. While specific integrations for Cardiosense's heart failure platform are not explicitly detailed, the focus on providing clinical intelligence and decision support suggests a need for interoperability with healthcare IT systems to maximize utility in various care settings. Data captured by the CardioTagu2122 device can be reviewed in an online dashboard, providing information to doctors previously only available within the hospital setting.
What the Web Says
Cardiosense is a company that leverages wearable technology, signal processing, and deep learning to diagnose and assess cardiovascular diseases, particularly heart failure. Their primary product, the CardioTag device and PCWP Analysis Software, offers a noninvasive method to monitor cardiac function and estimate pulmonary capillary wedge pressure (PCWP), a key indicator for heart failure. The company has received FDA clearance for its CardioTag device and De Novo classification for its PCWP Analysis Software, highlighting its clinical-grade reliability and potential to transform heart failure management.
Overall: PositiveStrengths
- Noninvasive and accurate monitoring of cardiac function, including PCWP, which traditionally required invasive procedures.
- FDA authorized and validated against right heart catheterization, with accuracy comparable to implantable sensors.
- Enables early detection and proactive management of heart failure, potentially reducing hospitalizations.
- Utilizes multimodal sensing (ECG, PPG, SCG) and AI to provide comprehensive clinical intelligence.
- Easy-to-use CardioTag sensor deployable at point-of-care, bedside, clinic, or home.
- Rapid quantitative PCWP readings available in minutes.
Limitations
- Limited public reviews available on platforms like G2, Glassdoor, Capterra, and Reddit specifically for Cardiosense (the company).
- Some advanced features of related 'CardioSense - Heart Monitoring' app may require a subscription.
- The 'CardioSense - Heart Monitoring' app is intended for informational purposes only and not for medical use.
- General sentiment on Reddit regarding cardiology appointments and doctor responsiveness can be negative, though not directly related to Cardiosense's product.
Based on reviews from: Cardiosense Website, MedGrade, Startup Intros, Fierce Healthcare, MobiHealthNews, Apple App Store, Reddit
Last updated: 2026-07-01
Videos
News, demos, and interviews about Cardiosense.
Videos load interactively. If none appear, search YouTube for Cardiosense →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded Cardiosense.
Related Companies
QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]
Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]